Elicio Therapeutics (ELTX) Company Report

Elicio Therapeutics reported a net loss of $10.1 million ($0.60 per share) for the third quarter of 2025, an improvement from a net loss of $18.8 million ($1.39 per share) in Q3 2024.
The company observed fewer disease progressions and deaths than projected in the Phase 2 AMPLIFY-7P study for ELI-002 7P as of November 6, 2025, leading to an updated anticipation for the event-driven primary Disease-Free Survival (DFS) analysis in 1H 2026.
Elicio extended its cash runway through Q2 2026 by raising approximately $11.1 million through an at-the-market program since the beginning of Q3 2025, covering the anticipated primary DFS endpoint analysis.
The Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue the ELI-002 7P Phase 2 study without modifications, indicating preliminary efficacy signals and a favorable safety profile.

Nov 13, 2025, 9:04 PM

Elicio Therapeutics Reports Positive Immunogenicity Data for ELI-002 7P Phase 2 Trial

ELTX

New Projects/Investments

Elicio Therapeutics announced that 99% of evaluable patients (89 of 90) in its ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P generated robust mKRAS-specific T cell responses.
The observed T cell responses showed an average increase of 145.3x over baseline (median 44.3x), consistent with prior Phase 1 trials where such responses correlated with clinical activity.
An Independent Data Monitoring Committee recommended that the trial continue to the final analysis without modifications, which Elicio believes indicates preliminary signals of efficacy.
The final disease-free survival analysis for the AMPLIFY-7P trial is anticipated in the fourth quarter of 2025.

Sep 17, 2025, 12:16 PM

Get instant answers from SEC filings, earnings calls & more

Elicio Therapeutics (ELTX)